In this April 2024 feature for The Bluntness, Scott Mazza, co-founder and COO of Vitality CBD, explains the role cannabinoids play within the entourage effect, alongside terpenes and flavonoids. The article outlines how different cannabinoids, ranging from THC and CBD to lesser-known compounds like CBG and CBN, interact with the endocannabinoid system and with each other to shape therapeutic and experiential outcomes. Citing emerging research and a 2022 clinical trial, Mazza highlights why full-spectrum CBD products may deliver effects at lower doses, reinforcing the importance of compound synergy, product composition, and informed consumer experimentation.

In this article, Scott Mazza of Vitality CBD examines the role of flavonoids in shaping cannabis color, flavor, and aroma, alongside their lesser-known biological functions within the plant. The article explains how flavonoids interact with terpenes and cannabinoids as part of the entourage effect, potentially influencing therapeutic outcomes, particularly in full-spectrum formulations. Mazza also emphasizes the need for deeper research and informed consumer scrutiny, especially regarding product composition, testing standards, and claims around anxiety and other health applications.

This The Bluntness feature by Scott Mazza, co-founder and COO of Vitality CBD, explores how terpenes shape flavor, effects, and therapeutic outcomes beyond THC alone. Citing peer-reviewed research, Mazza explains how specific terpene–cannabinoid combinations (“chemovars”) are linked to differing levels of symptom relief for conditions such as pain, anxiety, and depression. He argues that moving away from marketing-driven strain names toward chemical profiling is critical for advancing medical credibility, consumer transparency, and evidence-based cannabis use.

In this expert-led analysis, Scott Mazza of Vitality CBD explains why the “entourage effect”, the synergistic interaction of cannabinoids, terpenes, and flavonoids, is increasingly central to understanding CBD efficacy. Drawing on emerging clinical evidence, including anxiety studies comparing full-spectrum products to CBD isolates, Mazza outlines how full-spectrum formulations may achieve therapeutic effects at lower doses with fewer side effects. The article emphasizes the need for rigorous research to move the entourage effect from theory to practice and to inform higher scientific and manufacturing standards across the CBD industry.

In this op-ed, Scott Mazza of Vitality CBD examines Canada’s cannabis legalization missteps to outline practical lessons for New York as it rolls out adult-use sales. Drawing on Canada’s experience with overproduction, overregulation, and persistent illicit markets, Mazza argues that balanced supply, flexible regulation, and meaningful inclusion of legacy operators are essential to building a sustainable, competitive legal cannabis market in New York.

In this op-ed, Scott Mazza, co-founder and COO of Vitality CBD, argues that continued FDA inaction on approving CBD as a dietary supplement is putting consumers at risk and undermining industry credibility. Mazza explains how the lack of federal standards enables unsafe products and misleading claims, and calls for clear regulatory approval to legitimize CBD, protect consumers, and support evidence-based research and responsible manufacturers.

In this opinion piece, Scott Mazza, co-founder and COO of Vitality CBD, calls attention to widespread quality and compliance failures in New York’s CBD market, citing inaccurate labeling, contamination risks, and weak enforcement. Drawing on regulatory developments and industry investigations, Mazza urges stronger oversight alongside informed consumer pressure, arguing that transparent third-party testing and accountability are essential to protecting consumers and restoring trust in hemp-derived CBD products.